Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Resistant

ABSTRACT: These patients proved resistant to docetaxel treatment, exhibiting residual tumor of 25% or greater remaining volume. Keywords: repeat sample

ORGANISM(S): Homo sapiens

PROVIDER: GSE349 | GEO | 2003/06/26

SECONDARY ACCESSION(S): PRJNA104707

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcription profiling of human breast tumors resistant or sensitive to docetaxel treatment

Project description:This SuperSeries is composed of the following subset Series: GSE349: These patients proved resistant to docetaxel treatment, exhibiting residual tumor of 25% or greater remaining volume. Resistant GSE350 These patients were sensitive to docetaxel treatment, exhibiting less than 25% residual tumor.

2007-10-26 | E-GEOD-6434 | biostudies-arrayexpress

Transcription profiling of human sensitive and resistant tumours identify gene expression patterns in primary breast-cancer specimens that might predict response to taxanes.

Project description:These patients proved resistant to docetaxel treatment, exhibiting residual tumor of 25% or greater remaining volume.

2007-10-04 | E-GEOD-349 | biostudies-arrayexpress

Sensitive

Project description:These patients were sensitive to docetaxel treatment, exhibiting less than 25% residual tumor. Keywords: repeat sample

2003-06-26 | GSE350 | GEO

Transcription profiling of human breast cancer patients sensitive to docetaxel

Project description:These patients were sensitive to docetaxel treatment, exhibiting less than 25% residual tumor.

2008-06-12 | E-GEOD-350 | biostudies-arrayexpress

Genomic predictors of response to doxorubicin versus docetaxel in breast cancer

Project description:Low topo2a expression and ER-negative status were predictors of response to doxorubicin, while small tumor size and ER-negative status predicted response to docetaxel. Docetaxel was superior to doxorubicin in triple-negative/basal-like tumors, while no significant differences between these drugs were seen in the remaining intrinsic subtypes Keywords: reference x sample

2011-05-27 | GSE21997 | GEO

Expression data from prostate cancer Docetaxel-resistant cells

2012-10-02 | GSE36135 | GEO

Expression data from docetaxel-resistant and cabazitaxel-resistant prostate cancer cell lines

Project description:Docetaxel and cabazitaxel are the chemotherapy agents used in castration-resistant prostate cancer. However, most patients eventually develop resistance to these treatments. The aim of the study was to identify key molecular genes and networks associated with taxanes resistance in 2 models of docetaxel-resistant and cabazitaxel-resistant castration-resistant prostate cancer cell lines.

2020-10-25 | GSE158494 | GEO

Epigenetic profiling of docetaxel resistance in Breast Cancer

Project description:Illumina Infinium MethylationEPIC Beadchip was used to obtain DNA methylation profiles across 850000 CpGsites in nine different breast cancer PDX models. Docetaxel resistant and residual disease PDX models were also analyzed

2019-07-18 | GSE110184 | GEO

Expression data from docetaxel-resistant prostate cancer cell lines

Project description:Docetaxel-based chemotherapy is the standard first-line therapy in metastatic castration-resistant prostate cancer. However, most patients eventually develop resistance to this treatment. The aim of the study was to identify key molecular genes and networks associated with docetaxel resistance in 2 models of docetaxel-resistant castration-resistant prostate cancer cell lines.

2012-01-01 | GSE33455 | GEO

Expression data from Docetaxel-resistant prostate cancer cells

Project description:Docetaxel is the standard first line therapy for hormone-refractory prostate cancer patients. Here we generated models of Docetaxel resistance in prostate cancer cells to study the molecular pathways that drive the acquisition of resistance to this therapy. We used microarrays to detail the global program of gene expression underlying the acquisition of Docetaxel resistance in prostate cancer cells. Parental Docetaxel-sensitive prostate cancer cell lines (DU145 and 22Rv1) and selected Docetaxel-resistant cells (DU145-DR and 22Rv1-DR) were harvested for RNA extraction and hybridization on Affymetrix microarrays. Samples were analyzed in triplicates in order to increase the resolution of expression profiles.

2012-10-02 | E-GEOD-36135 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data